CRISPR Therapies, Base Editing and Approvals — 2026-09-11
Intellia Therapeutics’ CRISPR-based treatment for hereditary angioedema has received FDA acceptance for its Biologics License Application, setting a target approval date of March 2027. Meanwhile, CRISPR Therapeutics stock surged recently following positive clinical updates, highlighting investor optimism about the expanding in-vivo editing pipeline.
CRISPR Therapies, Base Editing and Approvals — 2026-09-11
Top developments
Intellia’s Lonvo-z Receives FDA BLA Acceptance for Hereditary Angioedema
On September 8, 2026, Intellia Therapeutics announced that the FDA accepted its Biologics License Application (BLA) for lonvo-z, an in-vivo CRISPR-Cas9 therapy for hereditary angioedema (HAE). The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 10, 2027. If approved, this would be the world’s first in-body gene-editing therapy. Clinical data showed an 87% reduction in monthly attacks compared to placebo, with 62% of patients remaining attack-free and off therapy for six months.
CRISPR Therapeutics Stock Surges on Pipeline Momentum
CRISPR Therapeutics (Nasdaq: CRSP) experienced a significant stock rally in early September 2026, driven by positive sentiment regarding its pipeline execution. Analysts cite the company’s progress in lipid-lowering gene editing therapies and broader platform value as key drivers. This movement contrasts with earlier volatility, signaling renewed investor confidence in the commercial viability of their Casgevy successors and next-generation candidates.
Cleveland Clinic Trial Confirms Safety of In-Vivo Cholesterol Editing
A first-in-human clinical trial at the Cleveland Clinic demonstrated that a one-time CRISPR-Cas9 infusion safely and continuously lowered LDL cholesterol and triglycerides over one year in patients with medication-resistant lipid disorders. This study reinforces the safety profile of systemic CRISPR delivery for cardiovascular disease, a major potential market for gene editing beyond rare disorders.
Local view
No recent local-language media coverage specific to this week's regulatory or clinical milestones was identified in the provided sources.
Context & numbers
- List Prices: Established CRISPR therapies like Casgevy maintain a list price of $2.2 million, while Lyfgenia is priced at $3.1 million. These figures continue to frame payer negotiations for upcoming in-vivo therapies like lonvo-z.
- Regulatory Timeline: The FDA’s acceptance of Intellia’s BLA places it in a competitive window against other late-stage candidates, with a decision expected in Q1 2027.
- Market Sentiment: Investor focus has shifted from initial platform validation to specific late-stage readouts, with CRISPR Therapeutics and Intellia leading market attention this week.
On the radar
- March 10, 2027: PDUFA date for Intellia’s lonvo-z, potentially marking the first approval of an in-vivo CRISPR therapy.
- Q4 2026: Additional updates expected from CRISPR Therapeutics’ lipid-lowering program (CTX310), particularly regarding durability of effect at higher doses.
- Safety Monitoring: Continued scrutiny of LNP delivery vehicles following previous safety signals in other in-vivo trials (e.g., Verve), with Intellia’s safety profile being closely watched by regulators.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
